Overview of Opioid Use Disorder

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Overview of Opioid Use Disorder"

Transcription

1 Overview of Opioid Use Disorder Doug Burgess, MD Medical Director of Outpatient Services, Truman Medical Centers Assistant Professor of Psychiatry, University of Missouri- Kansas City

2 Objectives History and epidemiology of opioid use disorders Why do people become addicted to opiates and why is it difficult to stop Overview of medication assisted treatment of opioid use disorders Questions

3

4 TABLE Drug relationships for withdrawal Methadone, 1 mg, is equivalent to Codeine, 30 mg Dromoran, 1 mg Fentanyl, 0.01 mg Heroin, 1 2 mg Hydrocodone, 0.5 mg Hydromorphone, 0.5 mg Laudanum (opium tincture), 3 ml Levorphanol, 0.5 mg Meperidine, 20 mg Morphine, 3 4 mg Oxycodone, 1.5 mg Paregoric, 7 8 ml Textbook of Substance Abuse Treatment, 4 th ed. Galanter, M.D., Marc.

5 Opiate Use - A Brief History 1980s Mass opiophobia leading to reports of pain undertreatment 1898 Heroin synthesized as safer, non-addictive upgrade from morphine, mass distribution 1970 Controlled Substances Act categorized regulated drugs under 5 schedules 2000s JCAHO deems pain fifth vital sign, opioid prescribing further increased dramatic rise in opioid misuse, abuse, ED visits 3400 BC Opium poppy cultivated in Mesopotamia 1800s Morphine isolated from opium, widely used in Civil War 1916 Oxycodone synthesized as safer upgrade from heroin 1990s New extendedrelease opioids, expanded use 2010s abusedeterrent formulations, education and public awareness, drug monitoring programs TIME [

6 SOURCE: National Institute on Drug Abuse,

7 A Growing Problem Chronic pain is defined as pain beyond the usual aches and pains that lasts for at least 3 months 10 % of all Americans report pain lasting longer than one year (Centers for Disease Control and Prevention, NATIONAL Center for Health Statistics 2006) The use of Chronic Opioid Therapy has increased dramatically over the last 20 years Emphasis on pain control (Now considered a vital sign) Aggressive marketing Decreased time spent with patients Improved treatment outcomes Change in patient expectations Not enough prescriber education

8

9

10

11

12 Missouri Prescribing Patterns?

13

14 Non-Prescription Use of Opioids In a month, 4.3 million Americans use prescription painkillers nonmedically Last year, 1.9 million Americans met criteria for prescription opioid use disorder Average age of first use 21.2 Despite increase in opioid prescriptions, there has been no overall change in amount of pain reported by Americans.

15 Age at time of Opioid Abuse/Misuse

16 Overdose On the Rise The most common drugs involved in OD include Methadone Oxycodone (OxyContin) Hydrocodone (Vicodin) More people died from drug OD in 2014 than any year on record. More than 6/10 involved an opioid. From , 165,000 Americans died from overdoses related to prescription opioids Americans die every day from overdose of prescription painkillers

17 Rates of Hospital Inpatient and ED Visits for Opioid Overuse by Region

18 60,000 Causes of Death in America ,000 40,000 30,000 20,000 10,000 0 Drug Overdoses HIV/AIDS Car Crashes Gun Homicides Source: Centers for Disease Control

19 Source Where Pain Relievers Were Obtained for Most Recent Nonmedical Use among Past Year Users Aged 12 or Older: Note: The percentages do not add to 100 percent due to rounding. 1 The Other category includes the sources "Wrote Fake Prescription," "Stole from Doctor's Office/Clinic/Hospital/Pharmacy," and "Some Other Way." Source: SAMHSA, 2011 National Survey Drug Use and Health

20 Heroin Use in the USA - Increasing 580 people initiate heroin use daily 2014 heroin OD deaths >10,500 (quadrupled from 2002) Mortality rate tripled since 2010, more than doubled among 18- to 25-yearolds Among new heroin users, approximately 75% report having abused prescription opioids prior to using heroin

21 Prescription Street Value - Roughly $1/mg - Large number of purchasers naive to illegal drug market so cost fluctuates So why do people move to heroin? - One study found availability is a large factor

22 DSM- 5 Criteria for Substance Use Disorder 2 or more of the following: Failure to fulfill obligations at work, home or school Recurrent use in hazardous situations Continued use despite recurrent social or interpersonal problems Tolerance Withdrawal Larger amounts/longer period than intended Persistent desire to cut back/quit Great deal of time using or recovering from use Social, occupational, recreational activities given up Continued use despite knowledge of physical, psychological consequences INTENSE CRAVING

23 Addictive Behavior = Survival Behavior Gone Awry (Courtesy of Steve LaRowe, PhD) Over the course of evolution, we have developed circuits in our brains that promote our survival. Drugs of addiction activate this survival circuitry to an exaggerated degree, and with chronic use, essentially take it over. In the late stages of addiction, an individual is basically a survivalist doing whatever it takes to acquire and use drugs regardless of the costs. Motivation has changed

24 Hijacking the Basic Survival Circuitry (Courtesy of Steve LaRowe, PhD)

25 Survival Circuits (Courtesy of Steve LaRowe, PhD) 1. Reward Circuitry -- LIKING 2. Memory Circuitry 3. Motivation, Drive Salience Circuitry CRAVING/WANTING 3. Orbital-Frontal Cortex 1. VTA 1. Nucleus Accumbens 2. Hippocampus 2. Amygdala

26 Opioid withdrawal Opioid Withdrawal Flushing Diarrhea Muscle cramps Flu-like sxs Nausea Agitation Hallucinations Stomach cramps Sleep problems Sweating STOP DRUG Days

27 Opioid Withdrawal Syndrome Protracted Symptoms Deep muscle aches and pains Insomnia, disturbed sleep Poor appetite Reduced libido, impotence, anorgasmia Depressed mood, anhedonia Drug craving and obsession

28 Environment Exposure Physical Illness Cognition Genes Traumatic Experiences Perceived Norms Substance Use Disorder Learned Coping Strategies Positive Effects Withdrawal Mental Illness Support Group Access to Treatment

29 Treatment of Opioid Use Disorder Prevention Education Patients and the public in general Physicians Monitoring Prescription Monitoring Programs Physician prescribing practices Access to appropriate Treatment for chronic pain Treatment Detoxification Limited efficacy- high relapse rates Treat co-morbid illnesses 12-step and community support groups

30 Medications for the treatment of withdrawal symptoms Symptom relief Autonomic excitability (jittery,restless)- clonidine Nausea/vomiting- perphenazine, ondansetron Diarrhea- Lomotil, loperamide Muscle cramps- cyclobenzaprine, methacarbamol Pain- NSAIDS Insomnia- trazodone, zolpidem

31 Medication Assisted Treatment (MAT) of Opioid Use Disorder Pharmacological Methadone: reduces mortality and morbidity, illicit drug use, criminal activity Suboxone (buprenorphine): more accessible, less potential for euphoric effects or overdose Naltrexone: perhaps better for patients with current employment, Sobriety as a contigency

32 Methadone Long acting opioid with limited euphoric effect Highly structured programs Ability to level up Dosing: mg/day Downsides: Limited access and flexibility Highly stigmatized Expensive and time consuming Can be associated with sedation, constipation and potentially dangerous interactions with other medications May be most appropriate for those with more severe opioid use disorders- highly structured treatment

33 Methadone regulations Regulated by Substance Abuse and Mental Health Services Administration (SAMHSA) and state agency Only provided in opiate treatment programs One year history of dependence and current use 18 and older, if younger must have failed 2 non opiate treatments in the prior 12 months and guardian consent Daily dosing, limited take home if doing well in the program Take home dose increases with successful time in clinic, up to 2 week supply after a year and a maximum of a month supply after 2 years Psychosocial treatments

34 Buprenorphine/naloxone (Suboxone) Regulation: Drug Addiction Treatment Act, (DATA 2000) allowing qualified physicians to prescribe Schedule III, IV, and V medications for the treatment of opioid addiction. MDs can receive training and obtain special permission from the DEA to prescribe this Makes opiate dependence treatment more accessible Required to refer to substance abuse treatment

35 Suboxone Partial activation of opioid receptor sites Prevents withdrawal and cravings Ceiling effect makes them safer in terms of overdose Opioids are unable to produce effect/euphoria Suboxone also contains naloxone Opioid receptor blocker Not absorbed sublingually Prevents injection

36 Partial vs. Full Opioid Agonist death Opiate Effect Full Agonist (e.g., methadone) Partial Agonist (e.g. buprenorphine) Dose of Opiate Antagonist (e.g. Naloxone)

37 Suboxone Dosing: 8 16 mg/day, ceiling of 24-32mg/day Most common side effects Constipation, sweating Usually not much sedative effect Potentially dangerous in patients with severe liver disease, uncontrolled alcohol use and use of other sedating medications

38 Buprenorphine/naloxone Three Stages of treatment: Induction: 2-3 day period of observed administration must be in mild to moderate opiate withdrawal Can be done in the hospital or in community setting Stabilization: Meeting weekly to monitor SE and cravings adjust dose to curb cravings and minimize withdrawal Maintenance: achieved sobriety stable dose

39 Rough Graph of Suboxone Induction Opiates Suboxone 20 0 Pre-Treatment Day 1 Day 2 Category 4

40 Naltrexone How it works: blocks opioids from binding to their receptors No effect from opiates Decreased cravings Patients have to be free from opioids for several days prior to starting this medication Can cause nausea, headaches and rare cases of liver damage. Prescription opiates will not work for pain control Available as a long acting injection (Vivitrol) Useful in individuals whose livelihood is contingent on sobriety

41 Duration of Treatment Substance use disorders are chronic diseases Genetics, life experiences, coping strategies, long term exposure to substances and other factors all contribute to the development of the condition. Not substituting one drug for another Decision to taper or stop is based on clinical picture and personal choices about treatment Like any other treatment, it is based on analysis of risk v. benefits

42

43 What treatment looks like html

44 Questions?

Opiate Use Disorder and Opiate Overdose

Opiate Use Disorder and Opiate Overdose Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5

More information

Treatment Alternatives for Substance Use Disorders

Treatment Alternatives for Substance Use Disorders Treatment Alternatives for Substance Use Disorders Dean Drosnes, MD, FASAM Associate Medical Director Director, Chronic Pain and SUD Program Caron Treatment Centers 1 Disclosure The speaker has no conflict

More information

Pharmacotherapy for opioid addiction. Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco

Pharmacotherapy for opioid addiction. Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco Pharmacotherapy for opioid addiction Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco Disclosure slide No commercial conflicts to disclose. Gaps in current treatment of opioid

More information

OPIOID DEPENDENCE. DR. SHILPA ADARKAR Associate Professor Dept Of Psychiatry & Deaddiction Centre, Seth GSMC & KEMH

OPIOID DEPENDENCE. DR. SHILPA ADARKAR Associate Professor Dept Of Psychiatry & Deaddiction Centre, Seth GSMC & KEMH OPIOID DEPENDENCE DR. SHILPA ADARKAR Associate Professor Dept Of Psychiatry & Deaddiction Centre, Seth GSMC & KEMH What is opioid? Opium, derived from the ripe seed capsule of the opium poppy (Papaver

More information

Tapering Opioids Best Practices*

Tapering Opioids Best Practices* Tapering Opioids Best Practices* Chuck Hofmann, MD, MACP 5 th Annual EOCCO Office Staff and Provider Summit September 28, 2017 Disclosure No Conflicts of Interest to report Learning Objectives Understand

More information

Medication Assisted Treatment of an Opioid Use Disorder. J. Craig Allen, MD. Medical Director, Rushford

Medication Assisted Treatment of an Opioid Use Disorder. J. Craig Allen, MD. Medical Director, Rushford Medication Assisted Treatment of an Opioid Use Disorder J. Craig Allen, MD. Medical Director, Rushford Learning objectives At the conclusion of this activity, participants will be able to: Understand

More information

Treatment Approaches for Drug Addiction

Treatment Approaches for Drug Addiction Treatment Approaches for Drug Addiction NOTE: This fact sheet discusses research findings on effective treatment approaches for drug abuse and addiction. If you re seeking treatment, you can call the Substance

More information

Appendix F Federation of State Medical Boards

Appendix F Federation of State Medical Boards Appendix F Federation of State Medical Boards Model Policy Guidelines for Opioid Addiction Treatment in the Medical Office SECTION I: PREAMBLE The (name of board) recognizes that the prevalence of addiction

More information

Talking with your doctor

Talking with your doctor SUBOXONE (buprenorphine and naloxone) Sublingual Film (CIII) Talking with your doctor Opioid dependence can be treated. Talking with your healthcare team keeps them aware of your situation so they may

More information

GOALS AND OBJECTIVES

GOALS AND OBJECTIVES SUBOXONE AND VIVITROL: ARE THERE DISPARITIES SURFACING IN MEDICATION ASSISTED TREATMENTS? P R E S E N T E D B Y D R. K I AM E M AH A N I A H & D R. M Y E C H I A M I N T E R - J O R D AN GOALS AND OBJECTIVES

More information

OST. Pharmacology & Therapeutics. Leo O. Lanoie, MD, MPH, FCFP, CCSAM, ABAM, MRO

OST. Pharmacology & Therapeutics. Leo O. Lanoie, MD, MPH, FCFP, CCSAM, ABAM, MRO OST Pharmacology & Therapeutics Leo O. Lanoie, MD, MPH, FCFP, CCSAM, ABAM, MRO Disclaimer In the past two years I have received no payment for services from any agency other than government or academic.

More information

OPIOID WITHDRAWAL UW PACC BY SARA HAACK, MD, MPH INTEGRATED CARE TRAINING PROGRAM FELLOW UNIVERSITY OF WASHINGTON UW PACC

OPIOID WITHDRAWAL UW PACC BY SARA HAACK, MD, MPH INTEGRATED CARE TRAINING PROGRAM FELLOW UNIVERSITY OF WASHINGTON UW PACC Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences OPIOID WITHDRAWAL BY SARA HAACK, MD, MPH INTEGRATED CARE TRAINING PROGRAM FELLOW UNIVERSITY OF WASHINGTON OBJECTIVES

More information

Heroin What You Need to Know

Heroin What You Need to Know Heroin What You Need to Know More People Died from Drug Overdoses than Car Crashes and Gun Deaths in 2015 52,404 people died from drug overdoses (33,091 involved an opioid including heroin) 37,757 people

More information

Opioid Addiction Statistics

Opioid Addiction Statistics May 2017 Opioid Addiction Statistics Definitions Heroin Epidemic - As pill mills close, prescribing is becoming tighter, demand among younger users rise, and dealer s profits rise, addicts are turning

More information

Serious Mental Illness and Opioid Use Disorder

Serious Mental Illness and Opioid Use Disorder Serious Mental Illness and Opioid Use Disorder Serious Mental Illness and Opioid Use Disorders Arthur Robin Williams, MD MBE Columbia University, Department of Psychiatry Nick Szubiak, MSW, LCSW Director,

More information

Prepared by: Dr. Elizabeth Woodward, University of Toronto Resident in Psychiatry

Prepared by: Dr. Elizabeth Woodward, University of Toronto Resident in Psychiatry Prepared by: Dr. Elizabeth Woodward, University of Toronto Resident in Psychiatry In broad terms, substance use disorders occur when a substance is used in a compulsive manner with a lack of control over

More information

Buprenorphine addiction

Buprenorphine addiction Buprenorphine addiction Search 16-11-2013 High hopes for buprenorphine, an effective treatment for opioid addiction, have been tempered by a messy reality: health complications and deaths. The ATTC Network

More information

Buprenorphine for Family Medicine. Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17

Buprenorphine for Family Medicine. Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17 + Buprenorphine for Family Medicine Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17 + Disclosures No conflicts of interest Off-label use of medications + Who here: Has taken care of a patient

More information

DISCLOSURES MANAGEMENT OF OPIOID USE DISORDERS LECTURE COVERS. SUDs ARE IMPORTANT. I have nothing to declare

DISCLOSURES MANAGEMENT OF OPIOID USE DISORDERS LECTURE COVERS. SUDs ARE IMPORTANT. I have nothing to declare MANAGEMENT OF OPIOID USE DISORDERS DISCLOSURES Marc A Schuckit Distinguished Professor of Psychiatry, UCSD Medical School I have nothing to declare SUDs ARE IMPORTANT Affect > 20% of your patients Are

More information

the facts about BUPRENORPHINE for Treatment of Opioid Addiction

the facts about BUPRENORPHINE for Treatment of Opioid Addiction the facts about BUPRENORPHINE for Treatment of Opioid Addiction i I d been shot on the streets, I d been in detox. It was jails, institutions. Death, I knew, was imminent for me so I started my recovery

More information

Ethical Considerations Concerning Medication Assisted Treatment and Recovery

Ethical Considerations Concerning Medication Assisted Treatment and Recovery Ethical Considerations Concerning Medication Assisted Treatment and Recovery April 14, 2017 Professional Development Conference ETSU, Department of Social Work Dottie Saxon Greene, PhD, LCSW, LCAS, CCS,

More information

Medical Assisted Treatment of Opioid

Medical Assisted Treatment of Opioid Medical Assisted Treatment of Opioid Dependence with XR-NTX(Vivitrol) Michael McNamara DO, FACN Medical Director Mental Health Center of Greater Manchester Manchester NH Outline Overview of Opioid Dependence

More information

Opioid Task Force Kick-Off Meeting. February 29, 2016

Opioid Task Force Kick-Off Meeting. February 29, 2016 Opioid Task Force Kick-Off Meeting February 29, 2016 Scope of the Opioid Problem and Data Review Olivia Kasirye, MD, MS County Public Health Officer OVERVIEW The Opioid Epidemic Opioid Task Force Development

More information

Addiction. Concept of Addiction R. Corey Waller MD, MS, FACEP, FASAM Director, Center for Integrative Medicine

Addiction. Concept of Addiction R. Corey Waller MD, MS, FACEP, FASAM Director, Center for Integrative Medicine Addiction Concept of Addiction R. Corey Waller MD, MS, FACEP, FASAM Director, Center for Integrative Medicine Twitter: @rcwallermd Objectives Understand the Concept of Addiction Survival FOOD WATER DOPAMINE

More information

Aryeh Levenson, M.D. (ext 8597) March 26, 2012 SUBOXONE PROGRAM:

Aryeh Levenson, M.D. (ext 8597) March 26, 2012 SUBOXONE PROGRAM: Aryeh Levenson, M.D. alevenson@scf.cc (ext 8597) March 26, 2012 SUBOXONE PROGRAM: Opiate Addiction: History First seriously emerged iatrogenically with Civil War vets By late 19 th century, 2/3 of all

More information

FY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine

FY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine FY17 SCOPE OF WORK TEMPLATE Name of Program/Services: Medication-Assisted Treatment: Buprenorphine Procedure Code: Modification of 99212, 99213 and 99214: 99212 22 99213 22 99214 22 Definitions: Buprenorphine

More information

Opioid Antagonist Act

Opioid Antagonist Act Opioid Antagonist Act Intranasal Naloxone Administration Training Module for Initial Responders Public Service Training Session Public Training Session Provided By: West Virginia Office of EMS Endorsed

More information

How To Engage and Keep Youth and Families in Treatment: Focus on Opioid Use and Abuse

How To Engage and Keep Youth and Families in Treatment: Focus on Opioid Use and Abuse How To Engage and Keep Youth and Families in Treatment: Focus on Opioid Use and Abuse What You Need to Know about Opioids MDFT Engagement Strategies That Everybody Can Use Gayle Dakof, Ph.D. MDFT International,

More information

Understanding and Planning: A Prescription for Fighting Opioid Use Disorder

Understanding and Planning: A Prescription for Fighting Opioid Use Disorder Understanding and Planning: A Prescription for Fighting Opioid Use Disorder The rampant opioid misuse battering the nation represents one of the most virulent threats to employee welfare in the more than

More information

SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets. Risk Evaluation and Mitigation Strategy (REMS) Program

SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets. Risk Evaluation and Mitigation Strategy (REMS) Program SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets Risk Evaluation and Mitigation Strategy (REMS) Program Office-Based Buprenorphine Therapy for Opioid Dependence: Important Information for Prescribers

More information

Medication-Assisted Treatment for Opioid Addiction. Facts for Families and Friends

Medication-Assisted Treatment for Opioid Addiction. Facts for Families and Friends Medication-Assisted Treatment for Opioid Addiction Facts for Families and Friends A lot of times family members just think that there s just a say no type approach, that if you re not gonna get high, end

More information

Opiate Addiction: Treatment Perspectives

Opiate Addiction: Treatment Perspectives Opiate Addiction: Treatment Perspectives Daniel H. Angres M.D., Director, Positive Sobriety Institute Chief Medical Officer, RiverMend Health Addiction Services Adjunct Associate Professor of Psychiatry,

More information

Today s workshop is sponsored by BSAS

Today s workshop is sponsored by BSAS Today s workshop is sponsored by BSAS The Bureau of Substance Addiction Services: Provides access to addictions services for the uninsured Funds and monitors prevention, intervention, treatment and recovery

More information

Opiates: Use, Abuse, and Detection

Opiates: Use, Abuse, and Detection piates: Use, Abuse, and Detection Dr. Leo Kadehjian Palo Alto, California Abused Prescription Drugs pioids CS Depressants Morphine, codeine, etc. xycodone (xycontin) Buprenorphine Methadone entanyl Meperidine

More information

Opiates. Justine Biragane, McKaylee Copher, Lynsey Crumbie, Claire Jones

Opiates. Justine Biragane, McKaylee Copher, Lynsey Crumbie, Claire Jones Opiates Justine Biragane, McKaylee Copher, Lynsey Crumbie, Claire Jones History & Evolution Opiates are natural pain relievers that are derived from opium, found in poppy plants. The use of opiates dates

More information

Practical Tools to Successfully Taper Prescription Opioids. Melissa Weimer, DO, MCR

Practical Tools to Successfully Taper Prescription Opioids. Melissa Weimer, DO, MCR Practical Tools to Successfully Taper Prescription Opioids Melissa Weimer, DO, MCR Objectives Understand how to calculate morphine equivalents per day Understand the steps necessary to plan a successful

More information

Medication-assisted treatment (MAT): An effective intervention for opioid use disorder

Medication-assisted treatment (MAT): An effective intervention for opioid use disorder Medication-assisted treatment (MAT): An effective intervention for opioid use disorder Medication-assisted treatment (MAT) is evidence-based, highly effective and underused for millions struggling with

More information

Opioid Abuse in Iowa Rx to Heroin. Iowa Governor s Office of Drug Control Policy March 2016

Opioid Abuse in Iowa Rx to Heroin. Iowa Governor s Office of Drug Control Policy March 2016 1 Opioid Abuse in Iowa Rx to Heroin Iowa Governor s Office of Drug Control Policy March 2016 2 National Rx Painkiller Trends CDC, 2013 3 National Rx-Heroin Trends NIH, 2015 4 National Rx-Heroin Trends

More information

DSM-5 AND ASAM CRITERIA. Presented by Jaime Goffin, LCSW

DSM-5 AND ASAM CRITERIA. Presented by Jaime Goffin, LCSW DSM-5 AND ASAM CRITERIA Presented by Jaime Goffin, LCSW MODULE 1: GOALS & OBJECTIVES What is your experience with using ASAM and DSM 5 criteria? What are your learning expectations for today? GOAL FOR

More information

Best Practices in Prescribing Opioids for Chronic Non-cancer Pain

Best Practices in Prescribing Opioids for Chronic Non-cancer Pain Best Practices in Prescribing Opioids for Chronic Non-cancer Pain Disclosures S C O T T S T E I G E R, M D, F A C P, D A B A M A S S I S T A N T C L I N I C A L P R O F E S S O R D I V I S I O N O F G

More information

Overview of the Opioid Addiction Epidemic

Overview of the Opioid Addiction Epidemic Overview of the Opioid Addiction Epidemic Presenter: Dr. Andrew Kolodny Moderator: Cindy Rodgers Audio will begin at 3:00PM ET. You can listen through your computer speakers or call 866-835-7973 Meeting

More information

Opiate Use among Ohio Medicaid Recipients

Opiate Use among Ohio Medicaid Recipients Opiate Use among Ohio Medicaid Recipients July 12, 2012 Ohio Colleges of Medicine Government Resource Center The Ohio State University College of Public Health Sponsored by The Ohio Department of Alcohol

More information

Substance Abuse Protracted Withdrawal

Substance Abuse Protracted Withdrawal Substance Abuse Protracted Withdrawal Overview 1. Acute and Protracted Withdrawal 2. Withdrawal Potential Kate Speck, PhD, MAC, LADC 3. Recovery Reinforcers 1 2 3 Addiction Addiction is a primary, chronic,

More information

Reducing Stigma and improving access to Medication Assisted Treatment for Drug and Alcohol use disorders. Presented by: Jim Scarpace ; LCPC

Reducing Stigma and improving access to Medication Assisted Treatment for Drug and Alcohol use disorders. Presented by: Jim Scarpace ; LCPC Reducing Stigma and improving access to Medication Assisted Treatment for Drug and Alcohol use disorders Presented by: Jim Scarpace ; LCPC Who is Gateway Alcohol & Drug Treatment? Largest Provider of Substance

More information

The Role of Primary Care Teams and the Medical Neighborhood in Addressing the Opioid Crisis in Maine. March 10, 2016

The Role of Primary Care Teams and the Medical Neighborhood in Addressing the Opioid Crisis in Maine. March 10, 2016 The Role of Primary Care Teams and the Medical Neighborhood in Addressing the Opioid Crisis in Maine March 10, 2016 Objectives Review current state of opioid crisis in Maine Briefly review physiology of

More information

Prescription Opioid Painkiller Public Opinion Poll

Prescription Opioid Painkiller Public Opinion Poll Prescription Opioid Painkiller Public Opinion Poll August, 2017 OBJECTIVES The overall objective of this research was to collect attitudes and views of prescription opioid painkillers among adults in Illinois.

More information

Overview of Medication Assisted Treatment Methadone, Buprenorphine and Naltrexone

Overview of Medication Assisted Treatment Methadone, Buprenorphine and Naltrexone Overview of Medication Assisted Treatment Methadone, Buprenorphine and Naltrexone Alexander Y. Walley, MD, MSc Associate Professor of Medicine Director, Addiction Medicine Fellowship Boston University

More information

Lobby Question. What are the specific challenges you are experiencing with opioid use in your communities?

Lobby Question. What are the specific challenges you are experiencing with opioid use in your communities? Lobby Question What are the specific challenges you are experiencing with opioid use in your communities? 1 CAPT WEBINAR September 6, 2017 Opioids Prevalence, Effects, and Pharmacology Hayden D. Center,

More information

Medication-assisted opioid addiction treatments: OB/GYN

Medication-assisted opioid addiction treatments: OB/GYN 5/13/16se Medication-assisted opioid addiction treatments: OB/GYN In October 2002, the Food and Drug Administration (FDA) approved buprenorphine monotherapy product, Subutex, and a buprenorphine/naloxone

More information

Colleen T. LaBelle, MSN, RN-BC,CARN Program Director, Office-Based Addiction Treatment Director, STATE OBAT Boston Medical Center

Colleen T. LaBelle, MSN, RN-BC,CARN Program Director, Office-Based Addiction Treatment Director, STATE OBAT Boston Medical Center Colleen T. LaBelle, MSN, RN-BC,CARN Program Director, Office-Based Addiction Treatment Director, STATE OBAT Boston Medical Center Disclosures I have no disclosures or commercial interests to report Addiction

More information

THE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE. Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept.

THE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE. Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept. THE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept. Public Health disclosures Dr. Martin has no conflict of interest to disclose.

More information

SUBOXONE FILM NEW PATIENT INTRODUCTION

SUBOXONE FILM NEW PATIENT INTRODUCTION SUBOXONE FILM NEW PATIENT INTRODUCTION Our clinic restricts our treatment panel to a limited number of pre-qualified patients. This program accepts only patients who are serious about overcoming opiate

More information

Medication Assisted Therapy(MAT) for Substance Use Disorders. Effective Integration of MAT and Psychosocial Treatments Bob werstlein PhD

Medication Assisted Therapy(MAT) for Substance Use Disorders. Effective Integration of MAT and Psychosocial Treatments Bob werstlein PhD Medication Assisted Therapy(MAT) for Substance Use Disorders Effective Integration of MAT and Psychosocial Treatments Bob werstlein PhD Medication Assisted Treatment Treatment for opioid addiction that

More information

Aligning Evidence-Based Practices with CCBHC Financing, Operations, and Quality Reporting. October 25th, :00pm 3:00pm

Aligning Evidence-Based Practices with CCBHC Financing, Operations, and Quality Reporting. October 25th, :00pm 3:00pm Aligning Evidence-Based Practices with CCBHC Financing, Operations, and Quality Reporting October 25th, 2017 2:00pm 3:00pm Webinar Login Directions Recommend calling in on your telephone. Enter your unique

More information

30 mg codeine vs 5 mg hydrocodone

30 mg codeine vs 5 mg hydrocodone 30 mg codeine vs 5 mg hydrocodone Gogamz Menu question: if 1 mg of suboxone is equal to 20-30 mgs of hydrocodone would that be the same for oxycontin would 1 mg of sub be equal to 20-30 mgs oxy then? Thanks.

More information

8/14/2017. Practical Approach to Office Based Addiction Treatment. Objectives. Foundation For Success Treating SUD

8/14/2017. Practical Approach to Office Based Addiction Treatment. Objectives. Foundation For Success Treating SUD Practical Approach to Office Based Addiction Treatment ELIZABETH A DAVIS, MD SOUTH END COMMUNITY HEALTH CENTER BOSTON, MA AUGUST 17, 2017 Objectives To understand Impact of addiction as a public health

More information

Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. A Treatment Improvement Protocol TIP

Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. A Treatment Improvement Protocol TIP Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction A Treatment Improvement Protocol TIP 40 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health

More information

VOLUME C. Pharmacological Treatment for Drug Use Disorders Drug Treatment for Special Populations

VOLUME C. Pharmacological Treatment for Drug Use Disorders Drug Treatment for Special Populations VOLUME C Pharmacological Treatment for Drug Use Disorders Drug Treatment for Special Populations Module 2 Basics of opioid dependence Pharmacotherapy options Opioids: Definition, effects and treatment

More information

Vermont Hub and Spoke Model Treatment Need Questionnaire

Vermont Hub and Spoke Model Treatment Need Questionnaire Vermont Hub and Spoke Model Treatment Need Questionnaire Friday, June 30, 2017 John Brooklyn, MD Assistant Professor of Family Medicine and Psychiatry University of Vermont Burlington, Vermont Webinar

More information

Opioid Management of Chronic (Non- Cancer) Pain

Opioid Management of Chronic (Non- Cancer) Pain Optima Health Opioid Management of Chronic (Non- Cancer) Pain Guideline History Original Approve Date 5/08 Review/Revise Dates 11/09, 9/11, 9/13, 09/15, 9/17 Next Review Date 9/19 These Guidelines are

More information

Dear DEA. Howard A. Heit, MD, FACP, FASAM,* Edward Covington, MD, and Patricia M. Good

Dear DEA. Howard A. Heit, MD, FACP, FASAM,* Edward Covington, MD, and Patricia M. Good PAIN MEDICINE Volume 5 Number 3 2004,* Edward Covington, MD, and Patricia M. Good *Georgetown University, Washington, District of Columbia; Cleveland Clinic Foundation, Cleveland, Ohio; Office of Diversion

More information

HIV/AIDS Definition: CDC Classification of HIV Infection Stage 1: Stage 2: Stage 3: Risk Factors

HIV/AIDS Definition: CDC Classification of HIV Infection Stage 1: Stage 2: Stage 3: Risk Factors HIV/AIDS Definition: Acquired immune deficiency syndrome (AIDS) is a progressive, incurable disease caused by the human immunodeficiency virus (HIV). Aids destroys the CD4+ T cells, impairing the immune

More information

Prescription Drug Abuse Task Force Rx Report Card

Prescription Drug Abuse Task Force Rx Report Card San Diego County Prescription Drug Abuse Task Force 2016 Rx Report Card October 2016 Key Measures of Prescription Drug and Heroin Problems in San Diego County. Visit www.sandiegorxabusetaskforce.org for

More information

AATOD Fact Sheet. Medication-Assisted Treatment for Opioid Use Disorder in the Justice System October 2017

AATOD Fact Sheet. Medication-Assisted Treatment for Opioid Use Disorder in the Justice System October 2017 AATOD Fact Sheet Medication-Assisted Treatment for Opioid Use Disorder in the Justice System October 2017 Introduction Many publications over the last decade have documented the alarming increase in use

More information

Opioid Overdose Best Practices Guideline. Table of Contents. A. General description: B: Typical signs and symptoms:

Opioid Overdose Best Practices Guideline. Table of Contents. A. General description: B: Typical signs and symptoms: Opioid Overdose Best Practices Guideline Table of Contents A. General description B. Typical signs and symptoms C. Expected course D. Making the diagnosis E. Recommended treatment F. Criteria for hospital

More information

Proper Use of ADHD Medication. Be AWARE

Proper Use of ADHD Medication. Be AWARE Proper Use of ADHD Medication Be AWARE ADHD Medications Stimulants Most Attention-Deficit/Hyperactivity Disorder (ADHD) medications are stimulants, such as amphetamine and methylphenidate. Stimulant medications

More information

SUBOXONE Sublingual Tablets Buprenorphine Hydrochloride + Naloxone Hydrochloride Consumer Medicine Information

SUBOXONE Sublingual Tablets Buprenorphine Hydrochloride + Naloxone Hydrochloride Consumer Medicine Information Sublingual Tablets Buprenorphine Hydrochloride + Naloxone Hydrochloride What is in this leaflet? This leaflet answers some common questions about. It does not contain all the available information. All

More information

Demystifying Buprenorphine Prescribing for Youth With Opioid Use Disorders. Providers Clinical Support System Opioid Therapies (PCSSO) CME 6/21/2017

Demystifying Buprenorphine Prescribing for Youth With Opioid Use Disorders. Providers Clinical Support System Opioid Therapies (PCSSO) CME 6/21/2017 Demystifying Buprenorphine Prescribing for Youth With Opioid Use Disorders Geetha A. Subramaniam MD, DFAACAP, DFAPA National Institute on Drug Abuse June 21, 2017 1 Providers Clinical Support System Opioid

More information

You will be prescribed a preparation in the strength of 1mg/1ml. Methadone, like heroin can also cause a physical dependence.

You will be prescribed a preparation in the strength of 1mg/1ml. Methadone, like heroin can also cause a physical dependence. METHADONE LEAFLET: What is Methadone? Methadone is a synthetic drug, used in the treatment of people who have a physical dependence to opiates, thereby preventing the onset of opiate withdrawal symptoms

More information

THE OPIUM POPPY OPIOID PHARMACOLOGY 2/18/16. PCTH 300/305 Andrew Horne, PhD MEDC 309. Papaver somniferum. Poppy Seeds Opiates

THE OPIUM POPPY OPIOID PHARMACOLOGY 2/18/16. PCTH 300/305 Andrew Horne, PhD MEDC 309. Papaver somniferum. Poppy Seeds Opiates OPIOID PHARMACOLOGY PCTH 300/305 Andrew Horne, PhD andrew.horne@ubc.ca MEDC 309 THE OPIUM POPPY Papaver somniferum Sleep-bringing poppy Poppy Seeds Opiates Opium Poppy Straw 1 OPIATES VS. OPIOIDS Opiates:

More information

Prescription Drug Abuse & Misuse: Neurobiology, Epidemiology, & EBPs

Prescription Drug Abuse & Misuse: Neurobiology, Epidemiology, & EBPs Prescription Drug Abuse & Misuse: Neurobiology, Epidemiology, & EBPs H. Westley Clark, M.D., J.D., M.P.H., CAS, FASAM Director Center for Substance Abuse Treatment Substance Abuse Mental Health Services

More information

Opioid Prescribing for Acute Pain. Care for People 15 Years of Age and Older

Opioid Prescribing for Acute Pain. Care for People 15 Years of Age and Older Opioid Prescribing for Acute Pain Care for People 15 Years of Age and Older Summary This quality standard provides guidance on the appropriate prescribing, monitoring, and tapering of opioids to treat

More information

Patient Initiation: Buprenorphine/Naloxone

Patient Initiation: Buprenorphine/Naloxone Patient Initiation: Buprenorphine/Naloxone Kristin Wason, MSN, APRN, CARN Office-Based Addiction Treatment Program Boston Medical Center *Images used for educational purposes only. All copyrights belong

More information

CONSENT FOR TREATMENT WITH NALTREXONE

CONSENT FOR TREATMENT WITH NALTREXONE CONSENT FOR TREATMENT WITH NALTREXONE Oral Naltrexone (Revia) and Extended-Release Injectable Naltrexone (Vivitrol) Naltrexone is a prescription medication that is used to: Prevent relapse to opiate/opioid

More information

Naloxone Intranasal EMT OPTIONAL SKILL. Cell Phones and Pagers. Course Outline 09/2017

Naloxone Intranasal EMT OPTIONAL SKILL. Cell Phones and Pagers. Course Outline 09/2017 EMT OPTIONAL SKILL Naloxone Intranasal Cell Phones and Pagers Be courteous to your classmates! Please set your cell phones and/or pagers to silent or turn them off. Course Outline Introduction and Overview

More information

Understanding Addiction: Why Can t Those Affected Just Say No?

Understanding Addiction: Why Can t Those Affected Just Say No? Understanding Addiction: Why Can t Those Affected Just Say No? 1 The Stigma of Addiction There continues to be a stigma surrounding addiction even among health care workers. Consider the negative opinions

More information

Law Enforcement Naloxone Training Florida Department of Children and Families. Office of Substance Abuse and Mental Health

Law Enforcement Naloxone Training Florida Department of Children and Families. Office of Substance Abuse and Mental Health Protecting, Leading, Uniting Since 1893 Law Enforcement Naloxone Training Florida Department of Children and Families Office of Substance Abuse and Mental Health 1. Learn how to recognize and respond to

More information

Addressing Substance Abuse To Improve Well-Being in Child Welfare Systems Current Trends, Continuing Challenges

Addressing Substance Abuse To Improve Well-Being in Child Welfare Systems Current Trends, Continuing Challenges Addressing Substance Abuse To Improve Well-Being in Child Welfare Systems Current Trends, Continuing Challenges Three Branch Institute on Child Well-Being July 1, 2014 Sid Gardner, MPA Drugs of the Decades

More information

Injectable naltrexone (XR-NTX) A RETROSPECTIVE STUDY OF ITS ACCEPTANCE IN A COMMUNITY RECOVERY SETTING BRIANNE FITZGERALD MSN, PMHNP, CARN-AP

Injectable naltrexone (XR-NTX) A RETROSPECTIVE STUDY OF ITS ACCEPTANCE IN A COMMUNITY RECOVERY SETTING BRIANNE FITZGERALD MSN, PMHNP, CARN-AP Injectable naltrexone (XR-NTX) A RETROSPECTIVE STUDY OF ITS ACCEPTANCE IN A COMMUNITY RECOVERY SETTING BRIANNE FITZGERALD MSN, PMHNP, CARN-AP Overview Gavin Foundation Injectable naltrexone Community report

More information

Morphine equivalent calculator suboxone

Morphine equivalent calculator suboxone Morphine equivalent calculator suboxone Gogamz Menu Best Way To Lose 30 Pounds In 6 Months Fat Burner Waist Belt Fat Burn And Target Heart Rate how much weight would i lose calculator Fastest Fat Burner

More information

A Different Kind of Drug War. CINDY SANDERS Posted: Thursday, April 5, :07 pm. Providers Focus on Prescription Drug Addiction, Abuse

A Different Kind of Drug War. CINDY SANDERS Posted: Thursday, April 5, :07 pm. Providers Focus on Prescription Drug Addiction, Abuse A Different Kind of Drug War CINDY SANDERS Posted: Thursday, April 5, 2012 4:07 pm Dr. Roland Gray recording the latest online prescribing class curriculum for the Prescription Safety Program. Providers

More information

Patient Information Leaflet. Opioid leaflet. Produced By: Chronic Pain Service

Patient Information Leaflet. Opioid leaflet. Produced By: Chronic Pain Service Patient Information Leaflet Opioid leaflet Produced By: Chronic Pain Service November 2012 Review due November 2015 1 Your Pain Specialist has recommended treatment with strong pain killers (opioids).

More information

Prescribing Framework for Naltrexone in Relapse Prevention (Opioid Dependence)

Prescribing Framework for Naltrexone in Relapse Prevention (Opioid Dependence) Hull & East Riding Prescribing Committee Prescribing Framework for Naltrexone in Relapse Prevention (Opioid Dependence) Patients Name: Unit Number: Patients Address:.. G.P s Name:.. Communication We agree

More information

Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction

Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction Andrew Kolodny, MD Co-Director, Opioid Policy Research Collaborative Heller School for Social Policy and Management Brandeis

More information

America s Addiction to Opioids: Heroin and Prescription Drug Abuse

America s Addiction to Opioids: Heroin and Prescription Drug Abuse Home» About NIDA» Legislative Activities» Testimony to Congress» America s Addiction to Opioids: Heroin and Prescription Drug Abuse America s Addiction to Opioids: Heroin and Prescription Drug Abuse Print

More information

Clinical Guidelines and Procedures for the Use of Naltrexone in the Management of Opioid Dependence Abbreviated Version

Clinical Guidelines and Procedures for the Use of Naltrexone in the Management of Opioid Dependence Abbreviated Version Clinical Guidelines and Procedures for the Use of Naltrexone in the Management of Opioid Dependence Abbreviated Version Clinical Guidelines and Procedures for the Use of Naltrexone in the Management of

More information

State of Minnesota. Preventing and Addressing Prescription Drug Abuse. Office of Minnesota Attorney General

State of Minnesota. Preventing and Addressing Prescription Drug Abuse. Office of Minnesota Attorney General State of Minnesota Opioids Preventing and Addressing Prescription Drug Abuse Office of Minnesota Attorney General Lori Swanson TABLE OF CONTENTS ACKNOWLEDGEMENT...1 SECTION 1. INTRODUCTION....2 SECTION

More information

INJECT PERCOCET

INJECT PERCOCET INJECT PERCOCET 10 325 Inject Percocet 10 325 And futures percocet molly The percocet time 3 tylenol same combination of and Percocet off molly effects of wear the and Percocet relief for pain 2 last week

More information

NIDA Quick Screen V1.0F1

NIDA Quick Screen V1.0F1 NIDA Quick Screen V1.0F1 Name:... Sex ( ) F ( ) M Age... Interviewer... Date.../.../... Introduction (Please read to patient) Hi, I m, nice to meet you. If it s okay with you, I d like to ask you a few

More information

SC MAT ACCESS. Medication Assisted Treatment Academic Community Capacity Expansion for Sustainable Success Kathleen Brady, MD, PhD, VPR, MUSC

SC MAT ACCESS. Medication Assisted Treatment Academic Community Capacity Expansion for Sustainable Success Kathleen Brady, MD, PhD, VPR, MUSC SC MAT ACCESS Medication Assisted Treatment Academic Community Capacity Expansion for Sustainable Success Kathleen Brady, MD, PhD, VPR, MUSC Overdose Death Rates from Opiates Most important sign of a

More information

V. EVIDENCE-BASED APPROACHES TO TREATING ADOLESCENT SUBSTANCE USE DISORDERS

V. EVIDENCE-BASED APPROACHES TO TREATING ADOLESCENT SUBSTANCE USE DISORDERS V. EVIDENCE-BASED APPROACHES TO TREATING ADOLESCENT SUBSTANCE USE DISORDERS R esearch evidence supports the effectiveness of various substance abuse treatment approaches for adolescents. Examples of specific

More information

Unintentional Drug Overdose Data Review

Unintentional Drug Overdose Data Review 28 Unintentional Drug Overdose Data Review Public Health - Dayton & Montgomery County Epidemiology Section May 2016 Page 1 of 26 Prepared by: Epidemiology Section of Public Health - Dayton & Montgomery

More information

15 mg morphine 10 mg hydrocodone

15 mg morphine 10 mg hydrocodone Cari untuk: Cari Cari 15 mg morphine 10 mg hydrocodone 3-2-2013 Convert From CALCULATED MORPHINE EQUIVALENT BY RESOURCE: Average ( mg ) Range ( mg ) Standard Deviation of Sample ( mg ) Hydrocodone. I usually

More information